About this trial
Postoperative ileus (POI) is a common complication after abdominal surgery, causing symptoms like nausea, vomiting, abdominal distension, and delayed passage of flatus and stool. Management remains challenging, with limited pharmacological options available. Prucalopride, a selective serotonin 5-HT4 receptor agonist, has shown promise in accelerating gastrointestinal recovery after surgery. However, the optimal timing and dosing for preventing POI remains unclear. Higher doses may provide more potent prokinetic effects in the postoperative setting. his study investigates if higher doses of prucalopride (4 mg) improve bowel function return and hospital stay in elective colorectal surgery patients compared to standard doses and placebo.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
undergoing elective colorectal surgery, including but not limited to colectomy, rectal resection, and sigmoid resection.
Disqualifiers
Emergency surgery
Total colectomy
Creation of a stoma
Pre-existing gastrointestinal disorders
Trial design
Parallel
Treatments tested in this trial
Prucalopride 2mg
DrugPrucalopride 2mg taken preoperatively
Prucalopride 4mg
DrugPrucalopride 4mg taken preoperatively
Standard Care
Other interventionStandard Supportive care
Treatment groups
Trial outcomes
Primary outcomes
time to first stool
time to tolerance of food
Secondary outcomes
time to first flatus
incidence of prolonged postoperative ileus
Sponsors and contacts
Click on the lead sponsor to view all of their trials.